InternationalÂ Journal of Biological Sciences 2009; 5(5):438-443
Â© Ivyspring International Publisher. All rights reserved
Gilles-Eric SÃ©ralini 1,2Â Â , JoÃ«l Spiroux de VendÃ´mois 2 , Dominique Cellier 2,3 , Charles Sultan 2,4 , Marcello Buiatti 2,5 , Lou Gallagher 6 , Michael Antoniou 7 , Krishna R. Dronamraju 8
1.University of Caen, Institute of Biology, Biochemistry, Esplanade de la Paix 14032 Caen Cedex France.
2.CRIIGEN, 40 rue Monceau, 75008 Paris France
3.University of Rouen, LITIS EA 4108, 76821 Mont Saint-Aignan, France
4.University of Montpellier, School of Medicine, IGH, CNRS, France
5.University of Firenze, Italy
6.Institute for Environmental Science and Research, Ltd, Crown Research Institute, Porirua, New Zealand
7.Kingâs College London School of Medicine, Dept. Medical and Molecular Genetics, London, United Kingdom
8.Foundation for Genetic Research, Houston, USA
Chronic health effects are increasing in the world such as cancers, hormonal, reproductive, nervous, or immune diseases, even in young people. During regulatory toxicological subchronic tests to prevent these on mammalian health, prior commercialization of chemicals, including pesticides and drugs, or GMOs, some statistically significant findings may be revealed. This discussion is about the need to investigate the relevant criteria to consider those as biologically significant. The sex differences and the non linear dose or time related effects should be considered in contrast to the claims of a Monsanto-supported expert panel about a GMO, the MON 863 Bt maize, but also for pesticides or drugs, in particular to re eal hormone-dependent diseases and first signs of toxicities.
Read Online : http://www.ijbs.com/v05p0438.htm